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Figure 1. MRI/MRV head and brain with sinus thrombosis involving the right internal jugular vein (A), sigmoid sinus (B) and entire right transverse sigmoid sinus (C).
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extension and speciﬁcally, no clot on the central venous
catheter. Patient was started on anticoagulation after which
her mentation improved gradually over several weeks.
Follow up MRI/MRV after two weeks of anticoagulation
showed persistence of the dural clot, but no extension. The
patient was discharged to the outpatient environment with
continued thrombosis on prolonged therapy and is currently
D+145 from transplant.
Patients undergoing stem cell transplantation (SCT) have
known risk factors for the development of VTE including the
underlying malignancy, chemotherapy regimens, immobility
during hospitalization and the use of central venous cathe-
ters. CVST is an unusual complication following SCT and was
heralded in this case by both dramatic clinical features and
subtle ﬁndings on imaging. It is unclear if CVST is extremely
rare or under-diagnosed post-transplant, and is a possible
element in the differential diagnosis of confusion in this
setting. Once detected, the dural thrombus persisted despite
prolonged anti-coagulation and steady improvement of pa-
tient’s sentinel symptoms.150
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Background: Preliminary data presented by our group at the
2014 ASBMTmeeting suggested a correlation between higher
CD34+ Cell-Dose Infused (CD34-CDI) during ASCTand shorter
time to ALC recovery for MM patients (pts). This updated
analysis which includes additional pts with longer follow-up
supports our prior results, and suggests a correlation between
higher CD34-CDI and decreased incidence of infections.
Methods: From 1/2012-1/2014, 21 consecutive MM pts who
had undergone ASCT were evaluated retrospectively to
determine the impact of CD34-CDI on ALCs and infectious
events. During the ﬁrst 100 days post-ASCT, all infectious
complications were noted and ALCs collected. Overall sur-
vival and progression free survival were monitored. ALC re-
covery was deﬁned as the ﬁrst day of three consecutive
measurements for the cutoff values: ALC  800, ALC  1000,and ALC  1500. Cox proportional hazard models were
applied to evaluate the association of CD34-CDI to ALC re-
covery. The signiﬁcance of the associationwas assessed using
the Log Rank Test since no competing risks were identiﬁed.
Additionally, the Nonparametric Wilcoxon Rank Sum Test
was used to determine the relationship between CD34-CDI
and the development of any infectious events.
Results: Of the 21 patients, 81% were male, 19% were female.
Median age was 62 years (range 45-71). Majority (62%) had
IgG MM and kappa light chain restriction (86%). Approxi-
mately 62% had ISS Stage II/III disease. Patients who had
received a higher CD34-CDI were more likely to achieve ALC
 800 (p¼0.040) and ALC  1000 (p¼0.021). For ALC re-
covery deﬁned as ALC  1500, no statistical signiﬁcance was
observed (p¼0.27). When CD34-CDI was < 4x106 cells/kg,
median times to ALC  800 and ALC  1000 were 33.5 and
41.5 days respectively, and were 19 and 22 days when CD34-
CDI was > 4x106 cells/kg. Pts without infections tended to
have higher CD34-CDI compared to those pts with infections
(p¼0.0452). Five of six pts with CD34-CDI < 4x106 cells/kg,
and three of 15 pts with CD34-CDI > 4x106 cells/kg devel-
oped at least one bacterial infectious complication. Among
pts who received CD34-CDI < 4x106 cells/kg, 60% of in-
fections (9 out of 15 events) occurred. With 17 months (mo)
of median follow-up (range 9-30 mo), ﬁve pts have relapsed
and one death has occurred. Four of ﬁve relapses, and the one
death received CD34-CDI > 4x106 cells/kg.
Conclusion: Higher CD34-CDI (> 4x106 cells/kg) may
shorten time to ALC recovery and limit infectious complica-
tions. Most relapses to date occurred in pts transplanted with
CD34-CDI > 4x106 cells/kg, raising the question of product
contamination with higher cell-doses. Additional follow-up
and larger prospective trials are needed to further deﬁne
optimal CD34-CDI that balances the beneﬁts of shortened
time to ALC recovery, minimizing infectious complications,
and decreasing risk of product contamination.
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